Capstone Investment Advisors LLC Takes $395,000 Position in Qiagen (NYSE:QGEN)

Capstone Investment Advisors LLC purchased a new position in shares of Qiagen (NYSE:QGEN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,696 shares of the company’s stock, valued at approximately $395,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Nuance Investments LLC boosted its stake in shares of Qiagen by 17.3% in the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after buying an additional 778,005 shares during the last quarter. Earnest Partners LLC grew its stake in Qiagen by 11.1% in the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock valued at $156,441,000 after purchasing an additional 379,679 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock valued at $133,292,000 after purchasing an additional 353,280 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Qiagen by 62.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after purchasing an additional 991,325 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Qiagen by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock valued at $105,726,000 after buying an additional 324,417 shares during the period. 70.00% of the stock is owned by institutional investors.

Qiagen Price Performance

Qiagen stock opened at $43.43 on Friday. The firm has a market capitalization of $9.91 billion, a P/E ratio of 111.36, a PEG ratio of 3.39 and a beta of 0.41. Qiagen has a one year low of $39.03 and a one year high of $47.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The business has a fifty day moving average price of $43.25 and a 200-day moving average price of $43.73.

Wall Street Analysts Forecast Growth

Several analysts have commented on QGEN shares. Robert W. Baird lifted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.